更新于：2024-11-01

Dysplasia

发育不良

更新于：2024-11-01

基本信息

别名

DYSPLASIA、DYSPLASIAS、Dyscrasia

+ [13]

简介

A usually neoplastic transformation of the cell, associated with altered architectural tissue patterns. The cellular changes include nuclear and cytoplasmic abnormalities. Molecular genetic abnormalities are also often found and, in some instances, may lead to cancer.

关联

项与发育不良相关的药物

Artesunate

青蒿琥酯

靶点

ATP2A1 x SERCA2

作用机制

ATP2A1抑制剂 [+1]

在研机构

Frantz Viral Therapeutics, LLC [+7]

原研机构

上海复星医药（集团）股份有限公司

在研适应症

疟疾 [+15]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

中国

首次获批日期1988-01-01

Bevacizumab-IRDye800CW(University of Groningen)

靶点

VEGF-A

作用机制

VEGF-A抑制剂

在研机构

University of Groningen [+1]

原研机构

University of Groningen

在研适应症

乳腺癌 [+7]

非在研适应症

腺瘤性结肠息肉病 [+6]

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期1800-01-20

Tozuleristide

靶点

chloride channel

作用机制

chloride channel调节剂

在研机构

Blaze Bioscience, Inc.

原研机构

Fred Hutchinson Cancer Research Center

在研适应症

发育不良 [+4]

非在研适应症

乳腺癌 [+4]

最高研发阶段临床1/2期

首次获批国家/地区-

首次获批日期1800-01-20

159

项与发育不良相关的临床试验

NCT06276764 / Not yet recruitingN/A

The LINFU® U.S. Registry for the Detection of Dysplasia and Pancreatic Ductal Adenocarcinoma (PDAC) in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)

In this study, LINFU® will be evaluated in patients who have been identified with IPMN to determine if it can be used to help identify early, pancreatic ductal adenocarcinoma and its noninvasive precursor lesions (dysplasia). The study will also help determine if LINFU® results in earlier intervention, treatment and improvement in patient outcomes.

开始日期2024-09-15

申办/合作机构

Adenocyte LLC

NCT06235619 / Not yet recruitingN/AIIT

CT Anatomical Characteristics of the Aortic Arch in Subjects With or Without Aneurysms Requiring Treatment

The aortic arch with a common origin of the innominate and left carotid artery (CILCA) prevalence in the general population is 13.6%. Its reputation as a benign anatomical variant has been ultimately shattered by further studies [3, 4, 8, 9] that identified the CILCA arch as a potential marker for thoracic aortic disease (TAD) The aim of this work is to report the CT anatomical characteristics of the aortic arch in subjects with or without aneurysms requiring treatment, in 5 major European cardiovascular centers.

开始日期2024-09-01

申办/合作机构-

NCT05790733 / RecruitingN/A

HYPNONAG : Therapeutic Communication Versus Traditional Method for Naso-gastric Intubation in Haematology: Randomized Controlled Clinical Study

Caloric intake is a determining factor in patients with hematological malignancies and hospitalized for prolonged aplasia following chemotherapy. The nutritional supplement is administered either parenterally or enterally through the placement of a nasogastric sonde (NGS). This last option has shown its advantage compared to parenteral nutrition in terms of preventing infections, the incidence of graft-versus-host disease in allograft patients, and the quality of resumption of oral nutrition during of returning home.
NGS allows the administration of an intake of 2000 calories/day, deemed necessary to mitigate the risk of undernutrition in patients hospitalized for more than 3 weeks and in the majority of cases unable to eat enough food mainly due to chemotherapy-induced mucositis. . The choice between enteral feeding by NGS and parenteral nutrition is the subject of controversial studies, with each team choosing one of the two options.
The installation of the NGS is often recognized as a traumatic gesture for patients but also invasive by caregivers.
The patient's anxiety, the intrusive and traumatic nature of the NGS can sometimes result in a failure of the gesture, a secondary refusal of the patient, or a reluctance of the caregiver to proceed with the gesture. Since 2013, NGS have been placed with the assistance of the nurse who practices hypnosis in the hematology department of the Rennes University Hospital. This invites the patient to pose his SNG without local anesthesia and in a completely autonomous way. The patient is thus able to place the NGS again if necessary during his hospitalization, and during subsequent hospitalizations. A retrospective and monocentric study carried out at the University Hospital of Rennes in 38 patients showed that all were able to perform NGS independently thanks to the hypnotic approach. It was observed a real comfort for the patient, and moreover this technique did not add extra work for the staff. The patient becomes autonomous and actor of his care.

开始日期2024-07-01

申办/合作机构

Centre Hospitalier Universitaire de Rennes

100 项与发育不良相关的临床结果

登录后查看更多信息

100 项与发育不良相关的转化医学

登录后查看更多信息

0 项与发育不良相关的专利（医药）

登录后查看更多信息

27,570

项与发育不良相关的文献（医药）

2025-02-01·Journal of Orthopaedics

Trochleoplasty and à-la-carte procedures for patellar instability in young and active patients: Clinical outcomes at minimum 2 Years follow-up

Article

作者: Sangaletti, Rudy ; Benazzo, Francesco ; Nesta, Fabio ; Montagna, Alice ; Andriollo, Luca ; Matascioli, Luca ; Rossi, Stefano MP. ; Rossi, Stefano Marco Paolo

IntroductionPatellar instability is a common condition affecting approximately 6 individuals per 100,000, but among adolescents, this incidence is notably higher. Trochlear dysplasia has been recognized as the pathoanatomic risk factor exerting the most significant biomechanical influence. Over time, various surgical techniques have been developed to address trochlear dysplasia. The purpose of this study is to evaluate the clinical outcomes, return to sport, as well as complications and re-operation rate of sulcus deepening trochleoplasty performed in a cohort of young and active patients using the Bereiter technique.Materials and methodsBetween January 2019 and February 2022, 11 cases of recurrent patellar dislocations underwent trochleoplasty. Preoperative radiological assessment included X-rays, CT scans following the Lyons and MRI. Inclusion criteria for the study and trochleoplasty indications included patients aged 10-25 with recurrent patellar dislocations unresponsive to nonoperative treatment and minimum type B trochlear dysplasia. Clinical follow-up occurred at 1-3-6 months and annually, with control X-rays at these intervals. Patient-reported outcome scores included the Knee Society Score, Kujala score, and Karnofsky performance status scale.ResultsBetween January 2019 and February 2022, 11 patients underwent trochleoplasty and were included in this study. Preoperative radiological measurements indicated mean values: sulcus angle (152.5°), trochlear depth (3.4 mm), Caton-Deschamps index (1.2), tibial tuberosity to trochlear groove (TT-TG) distance (17.5 mm), external patellar tilt angle (6.8°), femoral anteversion (11.5°), and tibial torsion (32°). All patients were followed up for at least 2 years, with an average of 43 months. Concurrent surgeries included tibial tuberosity transposition (100 %), MPFL reconstruction in 9 cases (81.8 %) and 2 patients also underwent division of the external alar ligament (18,2 %). PROMs at final follow-up showed mean values: Knee Society Score (KSS) (80.5), Kujala score (88.3), and Karnofsky performance status scale (88.8). Return to sport was reported by all active patients. Three cases required secondary surgical intervention for removal of the screws.ConclusionTrochleoplasty, especially with the Bereiter "thin flap" approach, improves patellofemoral congruency. Combining trochleoplasty with tibial tuberosity transposition addresses mal-tracking related to severe dysplasia and other à-la-carte procedures like medial patellofemoral ligament (MPFL) reconstruction enhance stability. In young and active patients, it resolves instability issues and reduces the likelihood of further dislocations with high return to sport rates.

2024-12-01·Tissue and Cell

Bromodomain containing 4 inhibition combats gastric precancerous lesions via modulating macrophage polarization

Article

作者: Zhu, Lei ; Zou, Xiaoming ; Cai, Qingxin ; Li, Gang

OBJECTIVEGastric precancerous lesions (GPL), characterized by intestinal metaplasia and dysplasia, marks a pivotal juncture in the transformation from gastritis to gastric cancer. Research on GPL could offer fresh perspectives on preventing cancer occurrence.METHODSThis study employed 1-methyl-3-nitro-1-nitrosoguanidine (MNNG) to establish GPL rat models and knocked BRD4 down in vivo to assess its impact on the lesions and macrophage morphology. Following that, the impacts of BRD4 knockdown on the malignant phenotypes of human gastric epithelial GES-1 cells were determined. Moreover, conditioned medium from macrophage was gathered and used for GES-1 cell culture. The involvement of macrophage polarization in the BRD4 regulatory mechanism in GES-1 cells was assessed.RESULTSThis study elucidated that MNNG induced an increase level of BRD4 in the rat models. BRD4 knockdown reduced lesions based on pathological sections and immunohistochemistry to detect proliferative antigens. Western blotting and immunofluorescence showed that BRD4 knockdown suppressed epithelial-mesenchymal transition and macrophage M2 polarization. In in vitro experiments, BRD4 knockdown inhibited the malignant phenotype of GES-1 cells and the differentiation of THP-1 cells into M2 macrophages, respectively. The conditioned medium from M2 macrophages with BRD4 knockdown was co-incubated with GES-1 cells, which attenuated the malignant phenotypes compared with the medium from M2 macrophages.CONCLUSIONThrough in vivo and in vitro experiments, BRD4 upregulation was found to already occur during GPL, affecting macrophage polarization and epithelial cell cancerization. This finding provides an experimental basis for strategies targeting BRD4 inhibition at this critical stage.

2024-12-01·The Journal of Pediatrics

Intubation and Lower Saturation in the Delivery Room are Associated with Balloon Atrial Septostomy in Neonates with Transposition of the Great Arteries

Article

作者: Naim, Maryam Y ; Ordonez, Maria ; Foglia, Elizabeth E ; Ades, Anne M ; Shillingford, Amanda J ; Rome, Jonathan J ; Dombroski, Madeline ; Bostwick, Anna L ; Kesman, Russell A ; Flohr, Sabrina ; Mathew, Leny ; O'Byrne, Michael L ; Reynolds, Tom ; Rychik, Jack ; Niccum, Maria ; Rintoul, Natalie E

OBJECTIVETo identify delivery room (DR) characteristics of patients with transposition of the great arteries (TGA) who underwent preoperative balloon atrial septostomy (BAS).STUDY DESIGNRetrospective cohort study of all patients with prenatally diagnosed TGA delivered at our center between 2013 and 2023 who underwent arterial switch operation during the newborn admission.RESULTSA total of 168 patients were included (median gestational age 39.5 weeks, 64% male, 33% with ventricular septal defect [VSD], 8% with aortic arch hypoplasia). BAS was performed in 84 patients (50%). Patients who underwent BAS had higher proportion of intubation in the DR (87% vs. 33%, p<0.001), lower maximum oxygen saturation in the first 10 minutes (64% vs. 74%, p<0.001) and 20 minutes (71% vs. 81%, p<0.001) of life, and lower maximum oxygen saturation at any point in the DR (79% vs. 87%, p<0.001). Adjusting for confounders (VSD, aortic arch anomaly, 5-minute Apgar, birth weight), intubation in the DR (adjusted odds ratio [aOR] 9.5, 95% CI 3.9, 25.0) and lower maximum oxygen saturation in the DR (aOR 0.9, 95% CI 0.8, 0.9) were independently associated with BAS. By receiver operating characteristic analysis, a maximum oxygen saturation of less than 86% at any timepoint in the DR discriminated for BAS with a specificity of 0.88, sensitivity of 0.70, and area under the curve of 0.82.CONCLUSIONSIntubation and lower oxygen saturation in the DR are independently associated with BAS in patients with TGA born at our center. A maximum DR saturation of less than 86% best discriminates patients who undergo BAS in our population.

131

项与发育不良相关的新闻（医药）

2024-10-29

·梅斯医学

OCIN 2024 | 梅斌教授：脑静脉窦狭窄&血栓诊疗进展

10月24日至27日，由上海市医学会、上海市医学会脑卒中专科分会主办的东方脑血管病会议2024（OCIN 2024）暨上海市医学会脑卒中专科分会学术年会在上海国际会议中心隆重召开。本届大会汇聚国内外众多专家学者和业界精英，分享脑血管病诊疗新技术、新理念。本次大会上，来自武汉大学中南医院的梅斌教授对“脑静脉窦狭窄&血栓诊疗进展“进行详解，本文梳理重点内容，以分享各位同道。 01 脑静脉窦简介脑静脉窦位于两层硬脑膜之间，壁内有很多毛细血管和小动脉，窦的内面有一层扁平细胞，是和静脉相连的内皮细胞。各静脉窦之间相互连通。Durgun等在1993年就已经通过造影证实，正常人群中只有 37.6% 的人在脑静脉窦回流通路中的双侧横窦和乙状窦是对称的，一般情况下把主要承担来自矢状窦和窦汇回流血液任务的一侧横窦和乙状窦称之为优势引流侧静脉窦，另一侧为非优势引流侧。脑静脉窦病变包括脑静脉窦狭窄，脑静脉窦血栓以及静脉窦发育不良。脑静脉窦狭窄是一个形态学的影像诊断，其原因可能是蛛网膜颗粒、血栓或外在压迫。这种形态学诊断可能会有临床意义（颅高压等），也可能无临床意义。脑静脉窦血栓是一个病理学诊断，可导致静脉窦狭窄或闭塞。静脉窦发育不良以一侧横窦发育不良最常见，仅为变异，非疾病，在特定情况下有临床意义。 Marmarou 等和 Stevens等研究认为，一般静脉窦狭窄处管径较正常管径缩窄 40% 以上可诊断静脉窦狭窄，而若管径较对侧缩窄 40% 以上，则考虑为静脉窦发育不全。在影像学诊断上，由于非优势引流一侧横窦常因血流减少而显影较差或者不显影，常被误认为存在横窦狭窄或者闭塞。 02 脑静脉窦狭窄脑静脉窦狭窄（VSS）是一种少见的脑血管疾病，每年发病率为1-2/100000，常见病因包括：内源性：静脉窦壁畸形（蛛网膜颗粒、瘢痕组织等)、静脉窦壁解剖变异(静脉分隔、盲袋结构)外源性：颅内占位、脑脊液压力升高脑静脉窦狭窄的临床症状为静脉窦狭窄若发生于优势一侧静脉窦可出现头痛，严重时可以导致静脉回流受阻，进而引起脑脊液的吸收障碍及颅内压升高，表现为头痛、视力下降等。脑静脉窦狭窄因血液湍流还可以出现搏动性耳鸣（PT）等症状。脑静脉窦狭窄导致颅内压升高的机制: ①静脉窦狭窄引起脑静脉回流障碍，脑静脉压力升高导致颅内压升高； ②静脉窦狭窄导致上矢状窦内静脉压升高，再引起上矢状窦内蛛网膜颗粒吸收脑脊液减慢，从而导致颅内压升高，最后升高的颅内压又会压迫静脉窦，导致静脉窦的进一步狭窄，从而形成恶性循环。影像学评估方法---DSA 1、DSA是诊断脑静脉窦狭窄的金标准由于DSA是一种有创性检查，单纯诊断静脉窦狭窄较少直接进行 DSA 检查。必须采用DSA的情况： ①通过其他手段无法明确静脉窦狭窄诊断；②需要排除硬脑膜动静脉痿等其他疾病时； DSA 检查+静脉窦内逆行造影+微导管测压术可更进一步判断静脉窦狭窄部位狭窄程度及窦内压力变化，有助于更准确了解静脉窦狭窄的程度和血流动力学状况，并判断患者是否适合介入手术。然而，DSA不足之处是不能提供静脉窦血管壁和近结构的解剖信息，不利于提供颅内静脉窦狭窄的原因。 2、脑静脉窦狭窄的新型诊断方法 Farb 等通过改进的自动触发螺旋型填充3D增强 MRV（ATECOMRV）分析上矢状窦-横窦-乙状窦影像，对左、右横窦及乙状窦的狭窄程度进行评分分级，结论认为ATECOMRV 的成像质量与 DSA 3D重建后图像类似，该方法尚有待于进一步通过大样本证实。动态 4D-MR 血管成像技术是一种动态评估手段，可以隐藏静脉前的动静脉分流影像从而完全显示个颅内静脉网，可分析静脉窦狭窄后血流动力学变化，特别是可显示狭窄附近形成的涡流，对静脉窦相关性耳鸣的诊断有重要意义。静脉血管内超声(IVUS)可以提供静脉窦内腔的 360°视图，并可同时显示静脉周围解剖结构，且无需对比剂。IVUS 可以和颅内静脉压测量同时进行，可精确测量狭窄的程度和长度，以及狭窄类型(内生型狭鹕踪窄和外压型狭窄)。介入治疗后，IVUS 还可用来评估治疗效果、监测再狭窄等(包括准确定位狭窄位置、描述狭窄部位形态学特征、鉴别支架内血栓)。因此，术前充分完善静脉窦狭窄相关无创影像学评估(包括 CT、MRI、CTV、MRV、MR BTI等），初步判断是否存在静脉窦狭窄，并结合多种影像学手段评估静脉窦狭窄段的形态、长度、部位、以及静脉侧支循环代偿状态。高度怀疑静脉窦狭窄后，建议进行DSA检查，明确静脉窦狭窄情况，并建议同期进行静脉窦内逆行造影及微导管测压术等，明确狭窄程度及狭窄段远近端压力差。几种新技术（自动触发螺旋型填充3D增强 MRV、动态 4D-MR 血管成像技术、静脉血管内超声）仍缺乏大样本支持，其准确性及有效性有待于进一步评估。 3、脑静脉窦狭窄的介入治疗方法症状性静脉窦狭窄主要的介入治疗方法为脑静脉窦支架置入术。与动脉病变不同的是，由于窦壁的弹性回缩及静脉血管内没有使之保持通畅的高压血流，因此静脉窦狭窄极少对单纯球囊扩张有效，只有支架可保证静脉窦的持续畅通。由于脑静脉窦管径较大，需要有一定径向支撑力且直径较大的血管支架系统，但颈静脉孔区的骨嵴结构难以通过较硬的外周支架输送系统，因此增加了介入手术的难度，使脑静脉窦支架技术的推广较为缓慢。 03 脑静脉窦血栓脑静脉窦血栓形成(CVT)约90%患者可出现头痛，颅高压20%~40% 患者可出现癫痫，20%~50% 出现局灶性神经功能缺损症状。CVT 的发生部位包括上矢状窦约占 25%~45%，直窦约 15%~18%，横窦约 25%~60%，皮层静脉约 15%~17%。CVT易感因素包括性别、激素水平、肿瘤、免疫、遗传等。 1、CVT动物模型的建立 Virchow血栓形成三要素包括改变血流状态、损害上矢状窦内皮、引起血液高凝状态。截至目前，在通过实验模型复制 CVT 的所有阶段，实现符合临床特征的转化研究仍然具有挑战。 2、CVT影像学评估方法 CT及 MR 是首选的诊断手段，可显示：①血栓直接征象②静脉流空影消失③静脉回流受阻继发改变（静脉性梗死、水肿、出血转化、颅高压、脑积水等）怀疑皮质静脉血栓时推荐 SWI、MRBTI 和T2*GRE序列；对慢性血栓，推荐增强 MRBTI 及 4D CE-MRV序列； 2，CVT治疗 ①抗凝治疗抗凝治疗是 CVT 治疗的核心手段。起始一般选择皮下注射低分子肝素，随后过渡为维生素 K拮抗剂（如华法林）口服3~12月，服药具体时间根据其病因及易感因素确定。 ②血管内治疗现阶段，EVT 主要作为 CVT 患者临床功能恶化时的补救治疗措施，并非首选方案。 ③去骨瓣减压去骨瓣减压用于重症CVT和即将发生脑疝的实质病变的患者。DECOMPRESS2 研究，一项在欧洲、亚洲和美洲10个国家15个中心进行的前瞻性多中心队列研究，收纳了118名接受去骨瓣减压的CVT患者，旨在评估12个月死亡和重度残疾(mRS 5-6)，次要结局为出院时死亡，6个月和12个月死亡、功能完全恢复(mRS 0-1)，功能独立(mRS 0-2)，严重残疾(mRS 4-5)。结果显示，研究发现近2/3的CVT患者在术后一年仍存活，超过1/3的患者能够独立生活，该结果为指南推荐的去骨瓣减压术提供了新的证据。来源 | 梅斯医学官网编辑 | Swagpp ● 持续热议！广东一公立医院欠薪数月，停诊破产后，医生：头次听说公立也会倒闭，我们这也欠薪，会步入后尘吗？二级医院艰难处境受到关注 ● 复旦大学惊人发现：仅3天的厨房烹饪油烟，就能引起肺炎和损伤肠道！持续7天更严重 ● 重磅！糖尿病是SGLT2抑制剂的禁忌症？第十版内科学出现错误，主编葛均波院士亲自回应！积极给教材挑错，本科教育要细之又细！版权说明：梅斯医学（MedSci）是国内领先的医学科研与学术服务平台，致力于医疗质量的改进，为临床实践提供智慧、精准的决策支持，让医生与患者受益。欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。点击下方「阅读原文」立刻下载梅斯医学APP！

2024-10-28

·PRNewswire

Previse Showcases New Data Highlighting Clinical Utility of Esopredict® Barrett's Esophagus Prognostic Test at ACG 2024

Epigenetic test for risk-stratification impacts gastroenterologists' decision making and improves confidence when caring for patients with Barrett's esophagus. BALTIMORE, Oct. 28, 2024 /PRNewswire/ -- Previse, a gastrointestinal health company, today announced the company presented prospective real-world clinical utility data for Esopredict at the 2024 American College of Gastroenterology Annual Scientific Meeting (ACG) being held October 25-30 in Philadelphia, PA and virtually. This presentation, awarded for Outstanding Poster Presentation, underscores Previse's commitment to clinicial impact and innovation with Esopredict, the first and only clinically validated and commercially available epigenetic test designed to aid gastroenterologists in optimizing care of patients diagnosed with precancerous Barrett's esophagus. About the poster presentation: Presentation Title: A COMMUNITY-BASED STUDY TO ASSESS A PROGNOSTIC ASSAY'S IMPACT ON GASTROENTEROLOGISTS' BARRETT'S ESOPHAGUS PATIENT SURVEILLANCE AND TREATMENT RECOMMENDATIONS The prospective study evaluates the clinical utility of real-world Esopredict testing in patients with Barrett's esophagus (BE) at multiple gastroenterology centers throughout the United States. Results demonstrate increased intensive surveillance and endoscopic treatment in higher risk patients, reduced surveillance in lower risk patients, and higher confidence in surveillance and treatment decisions. "The ACG Annual Scientific Meeting provides a premiere forum to showcase the real-world versatility of Esopredict, a prognostic solution that offers clinical value to gastroenterologists to support patient needs across the BE care spectrum," said Daniel Lunz, Chief Executive Officer at Previse. "This data demonstrates how Previse is transforming the care and treatment landscape for patients living with Barrett's esophagus." About Previse and Esopredict Established in 2018, Previse is a gastrointestinal health company with a primary focus on chronic acid reflux related diseases, including esophageal cancer. Previse's mission is to save lives and improve patient health through prevention and early detection. Previse leverages groundbreaking biomarker technology developed by Stephen Meltzer, M.D., and his GI Early Detection Biomarker Lab at the Johns Hopkins University School of Medicine. This technology, backed by funding from the National Institutes of Health (NIH) and decades of research, forms the foundation of Previse's commitment to combating GI diseases, including cancer. At the forefront is Esopredict, a highly sensitive epigenetic test designed to predict the risk of progression to high-grade dysplasia or esophageal adenocarcinoma in patients with precancerous Barrett's esophagus. With a turnaround time of about two weeks after a sample is received, Esopredict empowers gastroenterologists to tailor effective treatment strategies, marking a pivotal advancement in the battle against esophageal cancer. For additional information about Esopredict, please visit . SOURCE Previse WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2024-10-22

·PRNewswire

PREVISE RECEIVES $1.8M RESEARCH GRANT FROM THE NATIONAL INSTITUTES OF HEALTH TO FURTHER PIPELINE DIAGNOSTIC TEST

National Cancer Institute Phase II STTR funding will further the development of a non-endoscopic diagnostic for the detection of esophageal cancer in the US and East Africa. BALTIMORE, Oct. 22, 2024 /PRNewswire/ -- Previse, maker of Esopredict, a clinically available epigenetic test to assess the risk of esophageal cancer developing in patients with Barrett's esophagus was awarded a prestigious and highly competitive $1.8M STTR (Small Business Technology Transfer) grant by the National Cancer Institute (NCI) of the National Institutes of Health (NIH). The grant will further support Previse's collaboration with investigators at the Johns Hopkins University School of Medicine and clinical sites in East Africa. The funding will accelerate the development of a non-endoscopic screening test for esophageal squamous cell carcinoma (ESCC), a highly lethal form of esophageal cancer. The funds will also underpin early commercialization efforts in the U.S. and establish a commercialization pathway in East Africa, ensuring global access to accurate, affordable, and practical ESCC detection. Previse CEO Daniel Lunz said: "ESCC accounts for >80% of esophageal cancer deaths worldwide, including one-third of esophageal cancer cases occurring in the United States. Asian and Black populations are disproportionately affected by ESCC, representing a significant unmet need from a global public health perspective. These funds will advance this critically needed research, with the goal of bringing a highly effective and affordable non-endoscopic solution to market to expand access to earlier detection in the US and worldwide." About Previse and Esopredict Established in 2018, Previse is a gastrointestinal health company with a primary focus on chronic acid reflux related diseases, including esophageal cancer. Previse's mission is to save lives and improve patient health through prevention and early detection. Previse leverages groundbreaking biomarker technology developed by Stephen Meltzer, M.D., and his GI Early Detection Biomarker Lab at the Johns Hopkins University School of Medicine. This technology, backed by funding from the National Institutes of Health (NIH) and decades of research, forms the foundation of Previse's commitment to combating GI diseases, including cancer. At the forefront is Esopredict, a highly sensitive DNA methylation-based test designed to predict the risk of progression to high-grade dysplasia or esophageal adenocarcinoma in patients with precancerous Barrett's esophagus. With a turnaround time of about two weeks after a sample is received, Esopredict empowers gastroenterologists to tailor effective treatment strategies, marking a pivotal advancement in the battle against esophageal cancer. For additional information about Esopredict and full study details, please visit . SOURCE Previse WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED